ID

35127

Description

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Participants With Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02421185

Link

https://clinicaltrials.gov/show/NCT02421185

Keywords

Versions (1)
  1. 2/18/19 2/18/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 18, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Hepatocellular NCT02421185

English

Eligibility Carcinoma, Hepatocellular NCT02421185

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed hepatocellular carcinoma (hcc). for part 2, hcc participants must have fibroblast growth factor (fgf) 19 amplification in addition
Description

Liver carcinoma | FGF19 gene Amplification

Data type

boolean

Alias
UMLS CUI [1]
C2239176
UMLS CUI [2,1]
C1414603
UMLS CUI [2,2]
C0017256
participant must have advanced disease: disease ineligible for surgical or local-regional therapy or systemic therapy; disease progression after surgical or local-regional therapy; received no more than 1 line of systemic therapy
Description

Advanced disease | Disease Ineligible Operative Surgical Procedures | Disease Ineligible Therapy Local-Regional | Disease Ineligible Systemic therapy | Disease Progression Post Operative Surgical Procedures | Disease Progression Post Therapy Local-Regional | Systemic therapy Quantity

Data type

boolean

Alias
UMLS CUI [1]
C0679246
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C1512714
UMLS CUI [2,3]
C0543467
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C1512714
UMLS CUI [3,3]
C0087111
UMLS CUI [3,4]
C1947913
UMLS CUI [4,1]
C0012634
UMLS CUI [4,2]
C1512714
UMLS CUI [4,3]
C1515119
UMLS CUI [5,1]
C0242656
UMLS CUI [5,2]
C0687676
UMLS CUI [5,3]
C0543467
UMLS CUI [6,1]
C0242656
UMLS CUI [6,2]
C0687676
UMLS CUI [6,3]
C0087111
UMLS CUI [6,4]
C1947913
UMLS CUI [7,1]
C1515119
UMLS CUI [7,2]
C1265611
eastern cooperative oncology group (ecog) performance status score 0 or 1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate bone marrow, liver, renal function, and electrolytes according to protocol-defined criteria within the 14 days preceding the first dose of study drug
Description

Bone Marrow function | Liver function | Renal function | Electrolytes

Data type

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
UMLS CUI [4]
C0013832
negative pregnancy test (urinary or serum beta human chorionic gonadotropin [beta (b)-hcg]) at screening for women of child bearing potential
Description

Childbearing Potential Urine pregnancy test negative | Childbearing Potential Serum pregnancy test (B-HCG) Negative

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430057
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0430060
UMLS CUI [2,3]
C1513916
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
received systemic chemotherapy, targeted therapies, definitive radiotherapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or at least 5 half-lives of the drug, whichever is longer (in the case of nitrosoureas and mitomycin c, within 6 weeks) before the first administration of study drug
Description

Systemic Chemotherapy | Targeted Therapy | Therapeutic radiology procedure | Immunotherapy | Antineoplastic Agents Investigational | Nitrosoureas | Mitomycin

Data type

boolean

Alias
UMLS CUI [1]
C1883256
UMLS CUI [2]
C2985566
UMLS CUI [3]
C1522449
UMLS CUI [4]
C0021083
UMLS CUI [5,1]
C0003392
UMLS CUI [5,2]
C1517586
UMLS CUI [6]
C0028210
UMLS CUI [7]
C0002475
prior liver transplant
Description

Transplantation of liver

Data type

boolean

Alias
UMLS CUI [1]
C0023911
known fibrolamellar hcc or mixed cholangiocarcinoma and hcc
Description

Fibrolamellar Hepatocellular Carcinoma | Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0334287
UMLS CUI [2]
C0221287
clinically active serious infections greater than (>) common terminology criteria for adverse events (aes) grade 2
Description

Communicable Diseases Serious CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C1516728
participants with persistent calcium or phosphate > upper limits of normal (uln) during screening (within 14 days prior to day 1 of cycle 1 up until pre-dose of cycle 1) and despite medical management of calcium or phosphate levels
Description

Ca++ increased Persistent | Phosphate increased Persistent

Data type

boolean

Alias
UMLS CUI [1,1]
C0553702
UMLS CUI [1,2]
C0205322
UMLS CUI [2,1]
C0860988
UMLS CUI [2,2]
C0205322
Back to the top of the page

Similar models

Eligibility Carcinoma, Hepatocellular NCT02421185

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Liver carcinoma | FGF19 gene Amplification
Item
histologically or cytologically confirmed hepatocellular carcinoma (hcc). for part 2, hcc participants must have fibroblast growth factor (fgf) 19 amplification in addition
boolean
C2239176 (UMLS CUI [1])
C1414603 (UMLS CUI [2,1])
C0017256 (UMLS CUI [2,2])
Advanced disease | Disease Ineligible Operative Surgical Procedures | Disease Ineligible Therapy Local-Regional | Disease Ineligible Systemic therapy | Disease Progression Post Operative Surgical Procedures | Disease Progression Post Therapy Local-Regional | Systemic therapy Quantity
Item
participant must have advanced disease: disease ineligible for surgical or local-regional therapy or systemic therapy; disease progression after surgical or local-regional therapy; received no more than 1 line of systemic therapy
boolean
C0679246 (UMLS CUI [1])
C0012634 (UMLS CUI [2,1])
C1512714 (UMLS CUI [2,2])
C0543467 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C1512714 (UMLS CUI [3,2])
C0087111 (UMLS CUI [3,3])
C1947913 (UMLS CUI [3,4])
C0012634 (UMLS CUI [4,1])
C1512714 (UMLS CUI [4,2])
C1515119 (UMLS CUI [4,3])
C0242656 (UMLS CUI [5,1])
C0687676 (UMLS CUI [5,2])
C0543467 (UMLS CUI [5,3])
C0242656 (UMLS CUI [6,1])
C0687676 (UMLS CUI [6,2])
C0087111 (UMLS CUI [6,3])
C1947913 (UMLS CUI [6,4])
C1515119 (UMLS CUI [7,1])
C1265611 (UMLS CUI [7,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status score 0 or 1
boolean
C1520224 (UMLS CUI [1])
Bone Marrow function | Liver function | Renal function | Electrolytes
Item
adequate bone marrow, liver, renal function, and electrolytes according to protocol-defined criteria within the 14 days preceding the first dose of study drug
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0013832 (UMLS CUI [4])
Childbearing Potential Urine pregnancy test negative | Childbearing Potential Serum pregnancy test (B-HCG) Negative
Item
negative pregnancy test (urinary or serum beta human chorionic gonadotropin [beta (b)-hcg]) at screening for women of child bearing potential
boolean
C3831118 (UMLS CUI [1,1])
C0430057 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430060 (UMLS CUI [2,2])
C1513916 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Systemic Chemotherapy | Targeted Therapy | Therapeutic radiology procedure | Immunotherapy | Antineoplastic Agents Investigational | Nitrosoureas | Mitomycin
Item
received systemic chemotherapy, targeted therapies, definitive radiotherapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or at least 5 half-lives of the drug, whichever is longer (in the case of nitrosoureas and mitomycin c, within 6 weeks) before the first administration of study drug
boolean
C1883256 (UMLS CUI [1])
C2985566 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0021083 (UMLS CUI [4])
C0003392 (UMLS CUI [5,1])
C1517586 (UMLS CUI [5,2])
C0028210 (UMLS CUI [6])
C0002475 (UMLS CUI [7])
Transplantation of liver
Item
prior liver transplant
boolean
C0023911 (UMLS CUI [1])
Fibrolamellar Hepatocellular Carcinoma | Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Item
known fibrolamellar hcc or mixed cholangiocarcinoma and hcc
boolean
C0334287 (UMLS CUI [1])
C0221287 (UMLS CUI [2])
Communicable Diseases Serious CTCAE Grades
Item
clinically active serious infections greater than (>) common terminology criteria for adverse events (aes) grade 2
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
Ca++ increased Persistent | Phosphate increased Persistent
Item
participants with persistent calcium or phosphate > upper limits of normal (uln) during screening (within 14 days prior to day 1 of cycle 1 up until pre-dose of cycle 1) and despite medical management of calcium or phosphate levels
boolean
C0553702 (UMLS CUI [1,1])
C0205322 (UMLS CUI [1,2])
C0860988 (UMLS CUI [2,1])
C0205322 (UMLS CUI [2,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial